Evidence item

The result is specific to the RW2 real-world cohort of 14,644 patients, including 163 HGIN or EC cases, and compares EAGLE-Plus with the prior EAGLE model; the reported false-positive baseline is 432, reduced to 118, while sensitivity is 88.3% versus 89.8%. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 26049

Source: Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence · locator {} · excerpt hash sha256:698a9e3aa09fde24569896205d85057211c10f5d31279924905451c448dee661

In the RW2 cohort (n = 14,644), which included 163 cases of HGIN or EC, EAGLE-Plus led to a 72.7% reduction in FPs (from 432 to 118; Fig. 4a). Consequently, the PPV more than doubled, improving from 25.3% ... to 55.0% ... Regarding sensitivity, EAGLE-Plus (88.3% ...) maintained comparable performance to EAGLE (89.8% ...; P = 0.6186).